肾动脉介入栓塞术联合自体DC-CIK细胞免疫治疗中晚期肾癌的疗效观察
索杰，罗晓辉，巨育泉，刘建舟，门群利，李涛，黄晓东
（陕西省宝鸡市中心医院泌尿外科，陕西 宝鸡，721008）
浏览次数：71次 下载次数：378次
摘要：
目的 观察中晚期肾癌患者经肾动脉介入栓塞术联合DC-CIK细胞免疫治疗的临床效果。方法 将90例中晚期肾癌患者 按照治疗方法分为两组。试验组（n=47）采用DC-CIK细胞免疫联合介入栓塞化疗，对照组（n=43）仅进行介入栓塞化疗。观察治疗前、后两组患者细胞亚群及细胞因子水平变化情况、临床疗效、生存质量、体质量改善情况及不良反应。结果试验组CD3+、CD4+、CD8+、CD56+及CD4+/CD8+改善情况、临床疗效、KPS评分及体质量改善情况均优于对照组（P<0.05）；两组均未发生严重的 不良反应。结论 经肾动脉介入栓塞术合并DC-CIK细胞免疫治疗中晚期肾癌患者疗效显著，可显著改善患者的生存质量。
关键词：肾癌；肾动脉介入栓塞术；DC-CIK 细胞免疫疗法
中图分类号：R737.11 文献标志码：A文章编号：2096-1413(2017)18-0064-03
Efficacy of renal artery embolization combined with autologous DC-CIK cells in the treatment
of advanced renal cell carcinoma
SUO Jie, LUO Xiao-hui, JU Yu-quan, LIU Jian-zhou, MEN Qun-li, LI Tao, HUANG Xiao-dong
(Department of Urology, Baoji Central Hospital, Baoji 721008, China)
ABSTRACT: Objective To observe the clinical effect of renal artery embolization combined with autologous DC-CIK in the treatment of advanced renal cell carcinoma. Methods Ninety cases of patients with advanced renal cell carcinoma were divided into two groups according to different treatment methods. The experimental group (n=47) was treated with renal artery embolization chemotherapy combined with autologous DC-CIK, and the control group (n=43) received embolization chemotherapy. The changes of cell subsets and cytokine levels before and after treatment, clinical efficacy and adverse reactions were observed. Results The levels of CD3+, CD4+, CD8+, CD56+ and CD4+/CD8+, clinical effect, KPS score and body mass in the experimental group were significantly superior to those in the control group (P<0.05), and without adverse reactions occurring in the two groups. Conclusion Renal artery embolization combined with DC-CIK cell immunotherapy in the treatment of advanced renal cell carcinoma has significant effect, which can significantly improve the quality of life.
KEYWORDS: renal carcinoma; renal artery embolization; DC-CIK cell immunotherapy
参考文献：
[1] 黄道光,甘卫东.晚期肾癌近10年来治疗新进展[J].临床和实验医学杂志,2014,11(20):1729-1732.
[2] 叶定伟,张海梁.中国肾癌诊治现状和发展趋势[J].中华泌尿外科杂志,2014,35(6):401-405.
[3] 沙键,郦俊生,李立,等.肾细胞癌患者手术治疗的预后分析[J].实用癌症杂志,2015,30(1):124-126,132.
[4] 李威,高全立.转移性肾癌免疫治疗研究进展[J].国际免疫学杂志,2012,35(6):449-452.
[5] 谢晓冬,丁震宇.CIK 过继细胞免疫治疗恶性肿瘤技术临床应用现状[J].解放军医药杂志,2015,27(1):7-12.
[6] 李莉,王晓今,罗朝霞,等.DC/CIK细胞治疗恶性肿瘤的临床安全性研究[J].肝脏,2013,18(8):536-537.
[7] 赵鑫,常颖,刘玉侠,等.DC、CI 联合培养对肿瘤细胞杀伤作用的实验研究[J].中国实验诊断学,2015,19(10):1636-1638.